TheraRadar
← Back
Data updated: Mar 29, 2026

ESPERION THERAPS INC

Cardiovascular
Pharma

ESPERION THERAPS INC is a pharmaceutical company focused on Cardiovascular. Key products include NEXLETOL.

2020
Since
2
Drugs
-
Trials
8
Approved (2yr)

Key Drugs

NEXLIZET
bempedoic acid
Metabolic
ATP-citrate lyase 2 indications · 2020
NEXLETOL
bempedoic acid
Metabolic
ACSVL1 2 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

NEXLIZET 2026-01-09
Labeling
NEXLETOL 2026-01-09
Labeling
NEXLIZET 2025-11-21
Efficacy
NEXLETOL 2025-11-21
Efficacy
NEXLIZET 2025-07-21
Labeling
NEXLIZET 2025-07-21
Labeling
NEXLETOL 2025-07-21
Labeling
NEXLETOL 2025-07-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 100%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular
Merck big-pharma
Cardiovascular
Baxter specialty
Cardiovascular
Johnson & Johnson big-pharma
Cardiovascular
Bayer big-pharma
Cardiovascular